HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA has extended the decision deadline for AstraZeneca's experimental breast cancer pill, camizestrant, to review additional data after an advisory panel raised concerns about a late-stage trial's design. Brazil approved the first generic version of Novo Nordisk's Ozempic (now Ozivy) by EMS, a pharmaceutical company, which plans to sell it at 30% lower cost.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
- FDA expanding access to pancreatic cancer drug to some patients
- STAT+: Hims’ sales miss as telehealth competition grows
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more